Publications by authors named "Keith Purdy"
Article Synopsis
- - The study evaluated the effects of intravenous imatinib on patients with acute respiratory distress syndrome (ARDS) caused by COVID-19, focusing on its ability to reduce pulmonary edema.
- - In a randomized trial involving 66 patients, results showed no significant difference in pulmonary edema reduction or clinical outcomes between imatinib and placebo groups, although imatinib was found to be safe.
- - Interestingly, a subset of patients with high levels of specific inflammatory markers did benefit from imatinib treatment, indicating that targeted approaches may improve outcomes in certain ARDS patients.
Background: The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.
View Article and Find Full Text PDF